Short Interest in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Declines By 13.3%

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the recipient of a significant decline in short interest in September. As of September 15th, there was short interest totalling 5,200 shares, a decline of 13.3% from the August 31st total of 6,000 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 30,200 shares, the short-interest ratio is currently 0.2 days.

Hedge Funds Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC bought a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals accounts for 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 16th biggest position. Stonepine Capital Management LLC owned 6.86% of Kiora Pharmaceuticals as of its most recent filing with the SEC. 76.97% of the stock is currently owned by institutional investors.

Kiora Pharmaceuticals Stock Performance

KPRX opened at $3.43 on Friday. Kiora Pharmaceuticals has a 12 month low of $3.00 and a 12 month high of $8.98. The business has a 50-day moving average of $3.78 and a two-hundred day moving average of $4.67.

Kiora Pharmaceuticals (NASDAQ:KPRX) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.42. The company had revenue of $0.02 million for the quarter. Research analysts predict that Kiora Pharmaceuticals will post 1.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on KPRX. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Kiora Pharmaceuticals in a research note on Thursday, August 22nd. Maxim Group upgraded shares of Kiora Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, June 13th.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.